Topic: Cancer treatment
Dr Jenny Wang and her team have discovered a key self-renewal pathway essential for the survival of leukaemia-initiating cells.
Dr Latham’s team is pursuing the preclinical assessment and development of a novel class of drugs that aim to prevent cancer relapse by inhibiting the growth of cells that have already metastasised.
Dr Pidsley’s research will lead to the development of a novel sensitive epigenetic test, to accurately determine tumour risk, particularly for tumours that are inaccurately classified using current clinical tools.
Dr Beatriz Perez San Juan’s research is focussed on developing new targeted treatments for triple negative breast cancer that overcome the challenge of chemotherapy failure.
Professor Holst and Dr Centenera’s teams aim to develop a new drug treatment strategy to overcome resistance to hormone therapy in prostate cancer.
Associate Professor Thomas Cox and his team have identified a molecule in the lung tissue matrix called ‘Collagen IV’, which helps to control the behaviour of lung cancer cells.
Professor Murray Norris and his team will study RUNX1T1, building a detailed understanding of its role in maintaining normal function of embryonic stem cells, to develop a new way to treat childhood cancers.
Using high resolution molecular profiling technology, Associate Professor Gallego Ortega and his team have been studying MDSCs – trying to understand how they work, so they can develop treatments that block these cells.
In this project, Professor Lock and his team will investigate lncRNAs specifically in childhood AML.
Associate Professor Marina Pajic and her team have identified a molecular pathway that controls communication between pancreatic cancer cells and stromal cells.